Keyphrases
Cyclophosphamide
100%
Lymphoid Malignancies
100%
Granulocyte Colony-stimulating Factor (G-CSF)
100%
Fludarabine
100%
Duration of Response
66%
Complete Response
66%
Non-Hodgkin Lymphoma
50%
Chronic Lymphocytic Leukemia
50%
Reduced Dose
33%
Dosing Regimen
33%
Dose Reduction
33%
Partial Response
33%
Stage IV Disease
33%
Previous Treatment
33%
Thrombocytopenia
16%
Lost to Follow-up
16%
Previously Treated
16%
Stage III Disease
16%
Symptomatic Patients
16%
Pancytopenia
16%
Neutropenia
16%
6-cycles
16%
Heavily Pretreated Patients
16%
Maximum Response
16%
Pharmacology, Toxicology and Pharmaceutical Science
Cyclophosphamide
100%
Granulocyte Macrophage Colony Stimulating Factor
100%
Lymphoma
100%
Fludarabine
100%
Disease
83%
Nonhodgkin Lymphoma
50%
Chronic Lymphatic Leukemia
50%
Thrombocytopenia
16%
Neutropenia
16%
Pancytopenia
16%